Arginase therapy combines effectively with immune checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP301480
下载链接
链接失效反馈官方服务：
资源简介：
Comparing CD45+ cell transcriptional activity from murine CD45+ cells isolated from CT26 tumors 3 days after treatment with either Pegzilarginase, aOX40, or a combination of both
创建时间：
2021-01-14
